Hybrid Imaging in Oncology

  • Published : 2015.09.02


In oncology various imaging modalities play a crucial role in diagnosis, staging, restaging, treatment monitoring and follow up of various cancers. Stand-alone morphological imaging like computerized tomography (CT) and magnetic resonance imaging (MRI) provide a high magnitude of anatomical details about the tumor but are relatively dumb about tumor physiology. Stand-alone functional imaging like positron emission tomography (PET) and single photon emission tomography (SPECT) are rich in functional information but provide little insight into tumor morphology. Introduction of first hybrid modality PET/CT is the one of the most successful stories of current century which has revolutionized patient care in oncology due to its high diagnostic accuracy. Spurred on by this success, more hybrid imaging modalities like SPECT/CT and PET/MR were introduced. It is the time to explore the potential applications of the existing hybrid modalities, developing and implementing standardized imaging protocols and train users in nuclear medicine and radiology. In this review we discuss three existing hybrid modalities with emphasis on their technical aspects and clinical applications in oncology.


  1. Aspinall MG, Hamermesh RG (2007). Realizing the promise of personalized medicine. Harv Bus Rev, 85,117-65.
  2. Amoui M, Akbari ME, Tajeddini A, et al (2012). Value of sentinel lymph node biopsy in breast cancer surgery with simple pathology facilities-An Iranian local experience with a review of potential causes of false negative results. Asian Pac J Cancer Prev, 13, 5385-89.
  3. Avram AM (2012). Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification. J Nucl Med, 53, 754-64.
  4. Blankespoor SC, Wu X, Kalki JK (1996). Attenuation correction of SPECT using X-ray CT on an emission-transmission CT system: myocardial perfusion assessment. IEEE Trans Nucl Sci, 43, 2263-74.
  5. Buck A, Nekolla S, Ziegler S, et al (2008). SPECT/CT. J Nucl Med, 49, 1305-19.
  6. Bockisch Am, Freudenberg LS, Schmidt D, Kuwert T (2008). Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging. Semin Nucl Med, 39, 276-89.
  7. Ben-Haim S, Ell P (2009). 18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response. J Nucl Med, 50, 88-99.
  8. Beyer T, Freudenberg LS, Townsend DW, Czernin J (2011). The future of hybrid imaging-part 1: hybrid imaging technologies and SPECT/CT. Insights Imaging, 2, 161-69.
  9. Beyer T, Townsend DW, Czernin J, Freudenberg LS (2011). The future of hybrid imaging-part 2: PET/CT. Insights Imaging, 2, 225-34.
  10. Castellino RA, Hilton S, O'Brien P, et al (1996). Non-Hodgkin lymphoma: contribution of chest CT in the initial staging solution. Radiology, 199, 129-32.
  11. Czernin J, Allen-Auerbach M, Schelbert H (2007). Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med, 48, 78-88.
  12. Delso G, Furst S, Jakoby B, et al (2011). Performance measurements of the siemens mMR integrated whole-body PET/MR scanner. J Nucl Med, 52, 1-9.
  13. Even-Sapir E, Lerman H, Lievshitz G, et al (2003). Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. J Nucl Med, 44, 1413-20.
  14. Fontaine R, Belanger F, Viscogliosi N, et al (2009). "The hardware and signal processing architecture of LabPETTM, a small animal APD-based digital PET scanner. IEEE Trans Nucl Sci, 56, 3-9.
  15. Flohr TG, Ernst K, Thomas A, et al (2010). Pushing the envelope: new computed tomography techniques for cardiothoracic imaging. J Thorac Imaging, 25, 100-11.
  16. Hutton BF, Braun M, Thurfjell L, Lau DYH (2002). Image registration: an essential tool for nuclear medicine. Eur J Nucl Med Mol Imaging, 29, 559-77.
  17. Inaoka T, Takahashi K, Mineta M, et al (2007). Thymic hyperplasia and thymus gland tumors: differentiation with chemical shift MR imaging. Radiology, 243, 869-76.
  18. Jaszczak RJ, Coleman RE, Lim CB (1980). SPECT: Single photon emission computed tomography. IEEE Tran Nucl Sci, 27, 1137-53.
  19. Keidar Z, Israel O, Krausz Y (2003). SPECT/CT in tumor imaging: technical aspects and clinical applications. Semin Nucl Med, 33, 205-18.
  20. Kaya AO, Coskun U, Unlu M, et al (2008). Whole body 18FDG PET/CT imaging in the detection of primary tumors in patients with a metastatic carcinoma of unknown origin. Asian Pac J Cancer Prev, 9, 683-86.
  21. Lerman H, Metser U, Lievshitz G, et al (2006). Lymphoscintigraphic sentinel node identi?cation in patients with breast cancer: the roll of SPECT-CT. Eur J Nucl Med Mol Imaging, 33, 329-37.
  22. Lerman H, Lievshitz G, Zak O, et al (2007). Even-Sapir E. improved sentinel node identification by SPECT/CT in Overweight Patients with Breast Cancer. J Nucl Med, 48, 201-06.
  23. Liu J, Yang X, Li F, Wang X, Jiang X (2011). Preliminary study of whole-body diffusion-weighted imaging in detecting pulmonary metastatic lesions from clear cell renal cell carcinoma: comparison with CT. Acta Radiol, 52, 954-63.
  24. Liu NB, Zhu L, Li MH, Sun XR, et al (2013). Diagnostic value of 18F-FDG PET/CT in comparison to bone scintigraphy, CT and 18F-FDG PET for the detection of bone Metastasis. Asian Pac J Cancer Prev, 14, 3647-52.
  25. Mian C, Barollo S, Pennelli G, et al (2008). Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf), 68, 108-16.
  26. Moy L, Noz ME, Maguire GQ et al (2010). Role of fusion of prone FDG-PET and magnetic resonance imaging of the breasts in the evaluation of breast cancer. Breast J, 16, 369-76.
  27. Mainenti PP, Iodice D, Segreto S, et al (2011). Colorectal cancer and $^{18}$FDG-PET/CT: what about adding the T to the N parameter in loco-regional staging? World J Gastroenterol, 17, 1427-33.
  28. Mansi L, Ciarmiello A, Cuccurullo V (2012). PET/MRI and the revolution of the third eye. Eur J Nucl Med Mol Imaging, 39, 1519-24.
  29. Papathanassiou D, Liehn JC (2008). The growing development of multimodality imaging in oncology. Critical Rev Oncol Hematol, 68, 60-5.
  30. Petronis JD, Regan F, Lin K (1998). Indium-111 capromab pendetide (prostascint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med, 23, 672-77.
  31. Park JW, Kim JH, Kim SK, et al (2008). Choi JI, Lee WJ, Kim CM, Nam BH. a prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med, 49, 1912-21.
  32. Pichler BJ, Kolb A, Nagele T, Schlemmer HP (2010). PET/MRI: Paving the Way for the Next Generation of Clinical Multimodality Imaging Applications. J Nucl Med, 51, 333-36.
  33. Pace L, Nicolai E, Aiello M, Catalano OA, Salvatore M (2013). Whole-body PET/MRI in oncology: current status and clinical Applications. Clin Transl Imaging, 1, 31-44.
  34. Rufini V, Calcagni ML, Baum RP (2006). Imaging of neuroendocrine tumors. Semin Nucl Med, 36, 228-47.
  35. Sodee DB, Sodee AE, Bakale G (2007). Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med, 37, 17-28.
  36. Strauss LG, Conti PS (1991). The application of PET in clinical oncology. J Nucl Med, 32, 623-48.
  37. Shao Y, Cherry SR, Farahani K, et al (1997). Simultaneous PET and MR imaging. Phys Med Biol, 42, 1965-70.
  38. Schmidt GP, Schoenberg SO, Schmid R, et al (2007). Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol, 17, 939-49.
  39. Townsend D (2008). Multimodality imaging of structure and function. Phys Med Biol, 53, R1-R39
  40. Tateishi U, Hosono A, Makimoto A, et al (2009). Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann Nucl Med, 23, 155-61.
  41. Thamnirat K, Utamakul C, Chamroonrat V, et al (2015). Factors affecting disease-free status of differentiated thyroid carcinoma patients. Asian Pac J Cancer Prev, 16, 737-40.
  42. Vandecaveye V, De Keyzer F, Vander PV, et al (2009). Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging. Radiology, 251, 134-46.
  43. Watson CC, Casey ME, Bendriem B, et al (2005). Optimizing injected dose in clinical PET by accurately modeling the counting-rate response functions specific to individual patient scans. J Nucl Med, 46, 1825-34.
  44. Wahl RL, Quint LE, Cieslak RD, al (1993). "Anatometabolic" tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. J Nucl Med, 34, 1190-97.
  45. Wagner HN. (2005). A personal history of nuclear medicine. Springer, London .
  46. (visited 20.2.2014).
  47. Zaman M, Fatima N, Sajjad Z, Zaman Unaiza (2014). Whole body simultaneous PET/MRI: One-stop-shop? JPMA, 64, 201-05.